London, 21 October 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Polymerase Chain Reaction (PCR) Market 2014-2018, which is expected to post a CAGR of 9.19 percent during the forecast period of 2013-2018.
PCR is a molecular genetics technique used to amplify and analyze nucleic acids. It is a very precise, specific, and accurate technique that can amplify a specific DNA target from a mixture of DNA molecules and is used in a wide array of applications in research and diagnosis including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. The advances in PCR technology and tools provide high reproducibility in a short period.
“Contract research organizations are expanding their operations in the APAC region because of the low cost of conducting clinical trials in these countries. PCR helps CROs conduct drug discovery and toxicity studies easily and efficiently in a short period,” says Faisal Ghaus, Vice President of TechNavio.
“CROs employ the latest technologies and sophisticated instruments such as RT-PCR and qPCR for the clinical trials and product development, including toxicity studies.”
Key Market Drivers
- Advances in Technology
- Increased Focus on Research
- Demand for High-throughput Technology
- Increased Focus on Drug Discovery
Key Market Trends
- Increased M&As
- Increased Outsourcing Activities
- Increased Preference for Personalized Medicines
- Growth of CRO Industry in APAC Region
Key Market Vendors
- Abbott Laboratories
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- GE Healthcare
- Thermo Fisher Scientific Inc.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
